Barry, OppHub America Desk · · Source: yahoo-tickers-tape-movers
Abbott Labs, J&J: Dividend Kings Compared Amid Shifting Fortunes
Investors seeking consistent income from dividend-paying healthcare stocks may want to examine the contrasting performance and strategic initiatives of Abbott Laboratories and Johnson & Johnson. J&J has demonstrated stronger market outperformance this year, while Abbott Labs is undertaking acquisitions to bolster its diagnostics segment.
Based on reporting from yahoo-tickers-tape-movers.
Abbott Laboratories (ABT) and Johnson & Johnson (JNJ), both esteemed Dividend Kings, are navigating different paths. J&J has outperformed the market this year, while Abbott Labs has lagged, prompting an analysis of which healthcare giant presents a more compelling investment opportunity.
Market context for this story
As of: WeekendLoading quotes…
Informational only — not investment advice. Full markets →
$JNJJohnson & Johnson
TradingView
Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView chart — search any symbol in the widget. Confirm on /markets/JNJ and related $ABT. Not investment advice.
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
Abbott Laboratories ($ABT+WL +2.19%) and Johnson & Johnson ($JNJ+WL +1.07%), recognized for their consistent dividend increases over at least 50 consecutive years, are under scrutiny for investors seeking stable income. While both are classified as Dividend Kings, their market performance this year diverges, with J&J demonstrating market-beating strength and Abbott Labs trailing.
Abbott Laboratories is seeking a rebound after facing challenges including slower revenue and earnings growth in its diagnostics and nutrition segments, alongside legal and regulatory headwinds. The company's core medical device business, particularly its diabetes care unit featuring the FreeStyle Libre continuous glucose monitoring system, remains a key driver. The recent $21 billion acquisition of Exact Sciences, which includes the Cologuard colorectal cancer diagnostic test, aims to bolster its diagnostics division and tap into the cancer diagnostics market. Abbott has maintained its dividend growth streak for 54 years.
Johnson & Johnson, despite facing the loss of U.S. patent exclusivity for its immunosuppressant Stelara in 2025 and being subject to government drug price negotiations, has shown robust performance. The company's extensive pharmaceutical lineup continues to drive good revenue and earnings growth, potentially exceeding $100 billion in sales this year. Recent approvals, such as Icotyde for plaque psoriasis, are expected to strengthen its immunology portfolio. Johnson & Johnson's gross margin stands at 68.03% with a dividend yield of 1.94%.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
OppSHOP
Related to this story
Investors seeking consistent income from dividend-paying healthcare stoc
Shop related →
Investing books
Read the classics
Shop this pick →
Personal finance books
Run the household books
Shop this pick →
Trading notebooks
Write the thesis first
Shop this pick →
Monitor for charts
See every pane
Shop this pick →
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: August 23, 2026 at 9:25 PM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
healthcare dividends
Two reliable healthcare companies that have paid rising dividends for over 50 years are performing very differently this year. Experts are comparing Johnson & Johnson's steady success with Abbott Laboratories' efforts to bounce back through new business purchases.
What changed
Abbott and Johnson & Johnson show diverging market performance while pursuing different growth strategies like acquisitions and new drug approvals.
Who wins / who loses
Johnson & Johnson benefits from strong pharmaceutical sales, while Abbott Labs is working to overcome slower growth in its diagnostics and nutrition units.
Time horizon
Think in terms of the next few months.
Confidence & best fit
medium confidence · Long-term investor, Side income / builder
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $JNJBuild slowly — only if it fits your plan
Johnson & Johnson is making strong money from its medicines and is favored by investors looking for reliable income.
View $JNJ chart → · End-of-day delayed data
- $ABTWatch — track, don’t rush
Abbott Labs is lagging behind a bit right now, but it is buying other companies to help grow its medical testing business in the future.
View $ABT chart → · End-of-day delayed data
Peer
- $MDTWatch — track, don’t rush
Medtronic is a similar healthcare equipment company that helps show how the rest of the medical device industry is doing.
View $MDT chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Direction: volatile · Style: Covered-call income (only if you already own shares) · Level: intermediate
Like renting out part of your stock ownership for extra cash, but beginners should stick to simply buying and holding the shares.
Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Review personal portfolio exposure to healthcare sector concentration and dividend reinvestment plans.
What would break this thesis
- Unforeseen major regulatory roadblocks on pharmaceutical pricing or unexpected legal liabilities for either company.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.
Based on reporting from yahoo-tickers-tape-movers.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).